nach oben

Drugs

Erschienen in:

01.09.2004 | Adis Drug Profile

Amphotericin B Lipid Complex

In Visceral Leishmaniasis

verfasst von: David R. Goldsmith, Caroline M. Perry

Erschienen in: Drugs | Ausgabe 17/2004

Einloggen, um Zugang zu erhalten

Abstract

▴ Amphotericin B lipid complex is a lipid formulation of amphotericin B, an antifungal drug with activity against Leishmania spp. Amphotericin B lipid complex appears to enhance uptake of amphotericin B by infected macrophages in patients with visceral leishmaniasis (VL).
▴ In randomised, open-label, dose-ranging studies, short-course treatment with once-daily amphotericin B lipid complex (5–15 mg/kg total cumulative dose over 5 days), administered by intravenous infusion, produced high rates of apparent (day 19) [93–100%] and definitive (6 months) [79–100%] cures in Indian patients with antimonial-resistant VL.
▴ Amphotericin B lipid complex appeared to be as effective as liposomal amphotericin B or the conventional deoxycholate formulation in a randomised, open-label study conducted in India in a mixed population of patients with previously untreated or antimonial-resistant VL.
▴ In patients with HIV infection and VL, amphotericin B lipid complex 3 mg/kg/day for 5 or 10 days appeared to be as effective as meglumine antimonate 20 mg/kg/day for 28 days in a small randomised pilot study in southern Europe.
▴ Amphotericin B lipid complex was generally well tolerated in patients with VL. Infusion-related reactions were the most common adverse events associated with amphotericin B lipid complex.

The use of trade names is for product identification purposes only and does not imply endorsement.

Davidson RN. Practical guide for the treatment of leishmaniasis. Drugs 1998 Dec; 56(6): 1009–18PubMedCrossRef

Murray HW. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother 2001 Aug; 45(8): 2185–97PubMedCrossRef

Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997 Apr; 24(4): 684–703PubMedCrossRef

Davidson RN. AIDS and leishmaniasis. Genitourin Med 1997; 73: 237–9PubMed

Herwaldt BL. Leishmaniasis. Lancet 1999 Oct; 354(9185): 1191–9PubMedCrossRef

Elan Pharmaceuticals Europe. Abelcet: amphotericin B lipid complex: product monograph. 3rd ed. Cheshire: Gardiner-Caldwell Communications, 2000

Brajtburg J, Bolard J. Carrier effects on biological activity of amphotericin B. Clin Microbiol Rev 1996 Oct; 9(4): 512–31PubMed

Larabi M, Yardley V, Loiseau PM, et al. Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B. Antimicrob Agents Chemother 2003 Dec; 47(12): 3774–9PubMedCrossRef

Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents 2000 Feb; 13(4): 243–8PubMedCrossRef

10.

Piñero JE, Martinez S, del Castillo A, et al. In vitro susceptibility of Leishmania infantum strains isolated from Spanish HIV-positive patients to Abelcet and Fungizone [letter]. J Antimicrob Chemother 2002 Aug; 50(2): 304–6PubMedCrossRef

11.

Gangneux JP, Sulahian A, Garin YJ-F, et al. Lipid formulations of amphotericin B in the treatment of experimental visceral leishmaniasis due to Leishmania infantum. Trans R Soc Trop Med Hyg 1996 Sep–Oct; 90(5): 574–7

12.

Mullen AB, Carter KC, Baillie AJ. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob Agents Chemother 1997 Oct; 41(10): 2089–92PubMed

13.

Adedoyin A, Bernardo JF, Swenson CE, et al. Pharmacokinetic profile of Abelcet (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob Agents Chemother 1997 Oct; 41(10): 2201–8PubMed

14.

Adedoyin A, Swenson CE, Bolcsak LE, et al. A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections. Antimicrob Agents Chemother 2000 Oct; 44(10): 2900–2PubMedCrossRef

15.

Sundar S, Mehta H, Suresh AV, et al. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 2004 Feb; 38(3): 377–83PubMedCrossRef

16.

Sundar S, Agrawal NK, Sinha PR, et al. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med 1997 Jul; 127(2): 133–7PubMed

17.

Sundar S, Goyal AK, Mandai AK, et al. Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis. J Assoc Physicians India 1999 Feb; 47(2): 186–8PubMed

18.

Sundar S, Goyal AK, More DK, et al. Treatment of antimonyunresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex. Ann Trop Med Parasitai 1998 Oct; 92(7): 755–64CrossRef

19.

Laguna F, Videla S, Jiménez-Mejías ME, et al. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J Antimicrob Chemother 2003 Sep; 52(3): 464–8PubMedCrossRef

20.

López-Vélez R, Videla S, Márquez M, et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2004 Mar; 53(3): 540–3PubMedCrossRef

21.

Elan Pharma Ltd. Abelcet: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2004 Mar 15]

22.

Barrett JP, Vardulaki KA, Conlon C, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003 May; 25(5): 1295–320PubMedCrossRef

Titel: Amphotericin B Lipid Complex
In Visceral Leishmaniasis
verfasst von: David R. Goldsmith
Caroline M. Perry
Publikationsdatum: 01.09.2004
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 17/2004
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200464170-00004

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Amphotericin B Lipid Complex

In Visceral Leishmaniasis

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 17/2004

Manidipine

Amphotericin B lipid complex

Basis for the Management of Drug-Resistant Helicobacter pylori Infection

Androgen Replacement Therapy

High-Dose Chemotherapy in Breast Cancer

Amphotericin B Lipid Complex